Correction
The article published in [1] , contains incorrect data in Table 1 regarding the nationally recommended paediatric second-line ART regimen after NNRTI failure in India. This has been corrected. The editors and authors regret the inconvenience caused to readers by the error in the original paper. AZT+ddI+LPV/r AZT+ddI+LPV/r Newlands Clinic Zimbabwe AZT+3TC+NVP ddI+3TC+LPV/r d4T+3TC+NVP *Content reflects current recommendations at the time of the survey. WHO first-line regimen recommendations at the time of the survey included two NRTIs with one NNRTI or two NRTIs with one PI/r if the infant had previous NNRTI exposure [10, 17] ; second-line regimen recommendations after NNRTI failure included two NRTIs with one PI/r or unboosted nelfinavir in limited circumstances. d4T -stavudine; AZT -zidovudine; 3TC -lamivudine; NVP -nevirapine; EFV -efavirenz; ABC -abacavir; ddI -didanosine; LPV/r -ritonavir-boosted lopinavir; TDFtenofovir; FTC -emtricitabine; NRTI -nucleoside reverse transcriptase inhibitor; NNRTI -non-nucleoside reverse transcriptase inhibitor. 
